Patents by Inventor Elayne Penebre

Elayne Penebre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES WITH EHMT2 INHIBITORS
    Publication number: 20230364086
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 23, 2023
    Publication date: November 16, 2023
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Maria Alejandra RAIMONDI, Christine KLAUS, Elayne PENEBRE
  • Combination therapies with EHMT2 inhibitors
    Patent number: 11672800
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 13, 2023
    Assignee: Epizyme, Inc.
    Inventors: John Emmerson Campbell, Kenneth William Duncan, Maria Alejandra Raimondi, Christine Klaus, Elayne Penebre
  • METHODS OF USING EHMT2 INHIBITORS
    Publication number: 20230087806
    Abstract: The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 23, 2023
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Elayne PENEBRE, Kat COSMOPOULOS, Christine KLAUS
  • METHODS OF USING EHMT2 INHIBITORS IN TREATING OR PREVENTING BLOOD DISORDERS
    Publication number: 20210260040
    Abstract: The present disclosure relates to a method of preventing or treating a blood disorder (e.g., sickle-cell disease) via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: October 18, 2018
    Publication date: August 26, 2021
    Inventors: Elayne PENEBRE, Veronica GIBAJA, Maria Alejandra RAIMONDI
  • METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
    Publication number: 20210213014
    Abstract: The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.
    Type: Application
    Filed: October 18, 2018
    Publication date: July 15, 2021
    Inventors: Kat COSMOPOULOS, Elayne PENEBRE
  • PRMT5 inhibitors and uses thereof
    Patent number: 10653693
    Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 19, 2020
    Assignees: Epizyme, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael John Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash
  • METHODS OF USING EHMT2 INHIBITORS
    Publication number: 20200113901
    Abstract: The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 16, 2020
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Elayne PENEBRE, Kat COSMOPOULOS, Christine KLAUS
  • COMBINATION THERAPIES WITH EHMT2 INHIBITORS
    Publication number: 20200054635
    Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
    Type: Application
    Filed: April 20, 2018
    Publication date: February 20, 2020
    Inventors: John Emmerson CAMPBELL, Kenneth William DUNCAN, Maria Alejandra RAIMONDI, Christine KLAUS, Elayne PENEBRE
  • PRMT5 INHIBITORS AND USES THEREOF
    Publication number: 20170224685
    Abstract: Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 10, 2017
    Applicants: Epizyme, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Kenneth W. Duncan, Richard Chesworth, Paula Ann Boriack-Sjodin, Michael Munchhof, Lei Jin, Elayne Penebre, Olena I. Barbash